-- Scott Roberts
THURSDAY, Oct. 28 (HealthDay News) -- Sprycel (dasatinib) has
received an additional approval from the U.S. Food and Drug
Administration to treat a rare form of blood cancer called
Philadelphia chromosome positive chronic phase chronic myeloid
leukemia (Ph+ CP -CML), the agency said Thursday in a news
CML is a slowly progressive disease of the blood and bone marrow
that's believed related to a genetic abnormality, the FDA said.
Sprycel is among a class of drugs called oral kinase inhibitors,
which are thought to inhibit certain proteins that foster growth of
cancer cells. The drug was first approved in 2006 to treat other
forms of CML that are resistant to standard therapies, including
the Novartis anti-cancer drug Gleevec.
Sprycel's side effects could include decreased bone marrow
activity, fluid retention, diarrhea, headache, muscle and bone
pain, and rash.
Sprycel's maker, New York City-based Bristol-Myers Squibb, is
required as a condition of approval to conduct ongoing clinical
studies of the drug's long-term effectiveness for this condition,
the FDA said.
To learn more about CML, visit the U.S.
National Library of Medicine.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.